Asbell P A, Uçakhan O O, Abbott R L, Assil K A, Burris T E, Durrie D S, Lindstrom R L, Schanzlin D J, Verity S M, Waring G O
Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
J Refract Surg. 2001 Jan-Feb;17(1):25-31. doi: 10.3928/1081-597X-20010101-03.
To evaluate the reversibility of refractive effect following removal of the ICRS (intrastromal corneal ring segments; Intacs).
Data from 34 eyes from which ICRS were removed during United States FDA Phase II and III clinical trials were evaluated with regard to segment size, loss or change of best spectacle-corrected visual acuity (BSCVA), any change of uncorrected visual acuity (UCVA), manifest spherical equivalent refraction, manifest cylinder refraction, stability of manifest cylinder refraction, and subjective visual symptoms.
Out of 725 initial or contralateral eyes placed with the ICRS during Phase II and III clinical trials, segments were removed from 34 eyes (4.7%). Other than one (1/725, 0.1%) safety related ICRS removal, 30/725 (4.1%) were due to visual symptoms. ICRS removal was accomplished under topical anesthesia without complications in all eyes. The mean length of time the segments remained in the cornea after initial surgery was 10.3 +/- 5.4 months. At 3 months after ICRS removal, 21 eyes had monitored data available and were within +/-1 line or 10 letters of their preoperative BSCVA. Twenty eyes (20/21, 95%) returned to within +/-1.00 D of their preoperative manifest spherical equivalent refraction. All eyes had a stable refraction at the 3-month examination after removal, and a manifest spherical equivalent refraction within +/-1.00 D of their 1-month examination after removal. Nineteen eyes (19/21, 90%) returned to within +/-2 lines and 16 eyes (16/21, 76%) returned to within +/-1 line of preoperative UCVA.
The ICRS (Intacs) was easily and safely removed, and eyes returned to preoperative refractive status within 3 months.
评估移除ICRS(基质内角膜环片;Intacs)后屈光效果的可逆性。
对美国食品药品监督管理局II期和III期临床试验期间移除ICRS的34只眼的数据进行评估,内容包括片段大小、最佳眼镜矫正视力(BSCVA)的丧失或变化、裸眼视力(UCVA)的任何变化、显验光球镜等效度、显验光柱镜度数、显验光柱镜度数的稳定性以及主观视觉症状。
在II期和III期临床试验期间,725只初次或对侧眼中植入了ICRS,其中34只眼(4.7%)移除了片段。除1只眼(1/725,0.1%)因安全相关原因移除ICRS外,30/725(4.1%)是由于视觉症状。所有眼中ICRS移除均在表面麻醉下完成,无并发症。初次手术后片段在角膜内留存的平均时间为10.3±5.4个月。ICRS移除后3个月,21只眼有可监测数据,且其视力在术前BSCVA的±1行或10字母范围内。20只眼(20/21,95%)的显验光球镜等效度恢复到术前的±1.00D以内。所有眼在移除后3个月检查时屈光稳定,且显验光球镜等效度在移除后1个月检查时的±1.00D以内。19只眼(19/21,90%)的视力恢复到术前UCVA的±2行以内,16只眼(16/21,76%)恢复到术前UCVA的±1行以内。
ICRS(Intacs)易于安全移除,且眼在3个月内恢复到术前屈光状态。